178 related articles for article (PubMed ID: 33871162)
1. Oncolytic effect of Newcastle disease virus is attributed to interferon regulation in canine mammary cancer cell lines.
Santos MR; Xavier PLP; Pires PRL; Rochetti AL; Rosim DF; Scagion GP; de Campos Zuccari DAP; Munir M; Ferreira HL; Fukumasu H
Vet Comp Oncol; 2021 Sep; 19(3):593-601. PubMed ID: 33871162
[TBL] [Abstract][Full Text] [Related]
2. Newcastle disease virus LaSota strain induces apoptosis and activates the TNFα/NF-κB pathway in canine mammary carcinoma cells.
Wang J; Li M; Li M
Vet Comp Oncol; 2023 Sep; 21(3):520-532. PubMed ID: 37282822
[TBL] [Abstract][Full Text] [Related]
3. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
[TBL] [Abstract][Full Text] [Related]
4. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
[TBL] [Abstract][Full Text] [Related]
5. Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection.
Buijs PR; van Eijck CH; Hofland LJ; Fouchier RA; van den Hoogen BG
Cancer Gene Ther; 2014 Jan; 21(1):24-30. PubMed ID: 24384773
[TBL] [Abstract][Full Text] [Related]
6. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
[TBL] [Abstract][Full Text] [Related]
7. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the oncolytic property of recombinant Newcastle disease virus strain R2B in 4T1 and B16-F10 cells in-vitro.
Ramamurthy N; Pathak DC; D'Silva AL; Batheja R; Mariappan AK; Vakharia VN; Chellappa MM; Dey S
Res Vet Sci; 2021 Oct; 139():159-165. PubMed ID: 34332418
[TBL] [Abstract][Full Text] [Related]
9. Cell-type-specific innate immune response to oncolytic Newcastle disease virus.
Biswas M; Kumar SR; Allen A; Yong W; Nimmanapalli R; Samal SK; Elankumaran S
Viral Immunol; 2012 Aug; 25(4):268-76. PubMed ID: 22808996
[TBL] [Abstract][Full Text] [Related]
10. Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma.
Sánchez D; Pelayo R; Medina LA; Vadillo E; Sánchez R; Núñez L; Cesarman-Maus G; Sarmiento-Silva RE
Viruses; 2015 Dec; 8(1):. PubMed ID: 26703717
[TBL] [Abstract][Full Text] [Related]
11. Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion.
García-Romero N; Palacín-Aliana I; Esteban-Rubio S; Madurga R; Rius-Rocabert S; Carrión-Navarro J; Presa J; Cuadrado-Castano S; Sánchez-Gómez P; García-Sastre A; Nistal-Villan E; Ayuso-Sacido A
Cells; 2020 Jun; 9(6):. PubMed ID: 32516884
[TBL] [Abstract][Full Text] [Related]
12. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
13. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors.
Yaacov B; Eliahoo E; Lazar I; Ben-Shlomo M; Greenbaum I; Panet A; Zakay-Rones Z
Cancer Gene Ther; 2008 Dec; 15(12):795-807. PubMed ID: 18535620
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells.
Jiang K; Li Y; Zhu Q; Xu J; Wang Y; Deng W; Liu Q; Zhang G; Meng S
BMC Cancer; 2014 Jul; 14():551. PubMed ID: 25078870
[TBL] [Abstract][Full Text] [Related]
15. Autophagy inhibition suppresses Newcastle disease virus-induced cell death by inhibiting viral replication in human breast cancer cells.
Rozilah MI; Yusoff K; Chia SL; Ismail S
Virology; 2024 Feb; 590():109957. PubMed ID: 38100982
[TBL] [Abstract][Full Text] [Related]
16. The NDV-MLS as an Immunotherapeutic Strategy for Breast Cancer: Proof of Concept in Female Companion Dogs with Spontaneous Mammary Cancer.
Sánchez D; Cesarman-Maus G; Romero L; Sánchez-Verin R; Vail D; Guadarrama M; Pelayo R; Sarmiento-Silva RE; Lizano M
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543739
[TBL] [Abstract][Full Text] [Related]
17. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Schirrmacher V
Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
[TBL] [Abstract][Full Text] [Related]
19. Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus.
Puhlmann J; Puehler F; Mumberg D; Boukamp P; Beier R
Oncogene; 2010 Apr; 29(15):2205-16. PubMed ID: 20101224
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells.
Mansour M; Palese P; Zamarin D
J Virol; 2011 Jun; 85(12):6015-23. PubMed ID: 21471241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
